- Home
- OGS vs AXSM Comparison
OGS vs AXSM Comparison
Compare OGS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGS
- AXSM
- Stock Information
- Founded
- OGS 1906
- AXSM 2012
- Country
- OGS United States
- AXSM United States
- Employees
- OGS N/A
- AXSM N/A
- Industry
- OGS Oil/Gas Transmission
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- OGS Utilities
- AXSM Health Care
- Exchange
- OGS Nasdaq
- AXSM Nasdaq
- Market Cap
- OGS 4.3B
- AXSM 5.1B
- IPO Year
- OGS N/A
- AXSM 2015
- Fundamental
- Price
- OGS $73.11
- AXSM $108.98
- Analyst Decision
- OGS Buy
- AXSM Strong Buy
- Analyst Count
- OGS 6
- AXSM 17
- Target Price
- OGS $77.75
- AXSM $171.65
- AVG Volume (30 Days)
- OGS 565.6K
- AXSM 636.2K
- Earning Date
- OGS 08-05-2025
- AXSM 08-04-2025
- Dividend Yield
- OGS 3.66%
- AXSM N/A
- EPS Growth
- OGS 3.26
- AXSM N/A
- EPS
- OGS 4.20
- AXSM N/A
- Revenue
- OGS $2,260,428,000.00
- AXSM $432,157,000.00
- Revenue This Year
- OGS $22.29
- AXSM $62.84
- Revenue Next Year
- OGS $4.16
- AXSM $60.02
- P/E Ratio
- OGS $17.44
- AXSM N/A
- Revenue Growth
- OGS 7.73
- AXSM 72.16
- 52 Week Low
- OGS $63.69
- AXSM $72.21
- 52 Week High
- OGS $82.25
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- OGS 49.72
- AXSM 56.00
- Support Level
- OGS $71.74
- AXSM $102.26
- Resistance Level
- OGS $74.00
- AXSM $114.66
- Average True Range (ATR)
- OGS 1.15
- AXSM 3.49
- MACD
- OGS 0.22
- AXSM 0.92
- Stochastic Oscillator
- OGS 70.46
- AXSM 61.89
About OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. The company controls considerable market shares in Oklahoma and Kansas.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.